Keratoconus affects not only the cornea but also the retina, choroid, and optic nerve head, as shown in a meta-analysis co-authored by Prof. Farhad Hafezi.
Cataract surgery in keratoconus requires individualized biometry, conservative IOL choice, and careful corneal planning.
ELZA Institute’s Dr. Torres-Netto presents advances in surgical keratoconus treatment and ELZA-PACE-CXL at AAO 2025.
Prof. Hafezi was interviewed by Ocular Surgery News on his co-authorship of the II Global Consensus on Keratoconus – a landmark publication that will guide KC treatment for years to come.
Dr. Emilio Torres-Netto presented ELZA-PACE cross-linking at BRASCRS 2025, a customised, tissue-preserving keratoconus vision rehabilitation method with promising clinical outcomes.
CAIRS for keratoconus: Prof Hafezi and Dr. Torres-Netto are featured in Ocular Surgery News, in which CAIRS experts highlight its role in rehabilitating highly irregular corneas.
ELZA’s CEO, Nikki Hafezi launches a keratoconus screening initiative for children with Down syndrome in Uzbekistan, beginning in Andijan.
ECO-CAIRS extends tissue-based keratoconus surgery by optimizing allogenic ring segments through extracorporeal cross-linking.
At EgSCRS, ELZA’s pyramid approach to keratoconus: ELZA-sub400, PACE, ECO-CAIRS, and AI-guided diagnostics was presented in detail.
Hafezi addressed the widespread reliance on a 1986 prevalence estimate that places keratoconus at 1 in 2,000—formally classifying it as rare. Yet as she highlighted, emerging epidemiological data tell a starkly different story. Keratoconus is an orphan disease, not a rare one.
